Skip to content

Tibet Salt Reduction Study

Using Salt Substitute to Reduce Population Blood Pressure in Tibet: Tibet Salt Reduction Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02021435
Enrollment
4500
Registered
2013-12-27
Start date
2014-04-30
Completion date
Unknown
Last updated
2014-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure, Cardiovascular Diseases, Death

Brief summary

1. Research background \- High blood pressure is one of the most important risk factors to cardiovascular diseases (CVDs). Reducing population blood pressure can control CVD incidence and lower mortality effectively. Much research has proven that adjusting for Na and K intake level can reduce blood pressure. According to the China Salt Substitute Study, the systolic blood pressure of intervention group which used salt substitute is 5.4 mmHg lower than that of control group. Life expectancy in Tibet is 67 years old. It is estimated that the use of salt substitute among population in Tibet can reduce total mortality in Tibet by 20%. China Salt Substitute Study in Tibet (CSSS-Tibet), found that salt substitute is effective in lowering both systolic and diastolic blood pressure and offers a simple, low-cost approach for hypertension control among Tibetans in China (unpublished results). However, the study focused on hypertensive patients, the effectiveness of hypertension control by providing free salt substitute to the entire population remains unknown, and a large-scale trial is needed. 2. Objectives \- Primary objective is to observe the effect of providing salt substitute on population blood pressure in Tibet. Secondary objective is to observe the effect of such intervention on population mortality, cardiovascular mortality and life expectancy. In addition, the data collected from high-risk population (sub-group) in the study will be used in China Salt Substitute and Stroke Study (SSaSS). Also, serum cholesterol and random blood glucose of people over 60 in Tibet will be collected. 3. Method * The study is a open, cluster-randomized, controlled trial. * 30 villages with 15 to 35 households each and a distance of at least five kilometers in between will be selected from Damxung county and Maizhokunggar county. The two counties have an average altitude of over 4000 meters in Tibet Autonomous Region. * All selected villages will be randomly assigned to intervention group or control group on a 1:1 ratio. * All household in the selected villages will be recruited if they meet the eligibility criteria. Approximately 4,500 participants will be enrolled * Intervention group receives free salt substitute. Control group will continue to buy their own normal salt. Both group will receive the same health education on salt reduction. 4. Outcome - Primary outcome is blood pressure. Secondary outcomes include total mortality, cardiovascular disease mortality, life expectancy, serum cholesterol level of people over 60, and random blood glucose level of people over 60.

Interventions

DIETARY_SUPPLEMENTsalt substitute

Free salt substitute provided

Sponsors

The George Institute for Global Health at PUHSC
CollaboratorUNKNOWN
The George Institute for Global Health, Australia
CollaboratorOTHER
Science and Technology Department of Ningxia
CollaboratorUNKNOWN
People's Hospital of Tibet
CollaboratorUNKNOWN
People's Hospital of Maizhokunggar
CollaboratorUNKNOWN
Tibet University
CollaboratorOTHER
Peking University
CollaboratorOTHER
People's Hospital of Damxung County, Tibet
CollaboratorUNKNOWN
Beijing Jishuitan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* All family households in the selected satellite village will be invited to participate in the study Family households will be excluded from participating if they meet one or more of the following

Exclusion criteria

* Any member in the family is using a potassium-sparing diuretic * Any member in the family is using a potassium supplement * Any member in the family has serious renal impairment * Any member in the family over 18 could not sign informed consent * Life expectancy of any member in the family is shorter than 6 months in doctor's opinion

Design outcomes

Primary

MeasureTime frame
Difference in change from baseline in blood pressure between intervention and controlBaseline, 6,12, 24 months

Secondary

MeasureTime frame
Difference in total mortality between intervention and control6, 12, 24 months
Difference in cardiovascular disease mortality between intervention and control6,12, 24 months
Difference in life expectancy between intervention and control group6, 12, 24 months
The distribution of blood glucose level in population over 60 years oldbaseline
Distribution of serum cholesterol level in population over 60 years oldbaseline

Countries

China

Contacts

Primary ContactXingshan Zhao, M.D.
xingshanzh@gmail.com86-13701326978

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026